By attending this webinar, you will

  • Understand the current status of the EU Joint Clinical Assessment process, including timelines, procedural developments, and how Member States are engaging so far.
  • Gain clarity on the practical steps biopharma companies can take (and have taken) to prepare for EU HTA submissions, even amid ongoing uncertainty.
  • Explore the value of Joint Scientific Consultations (JSCs) in aligning regulatory and HTA evidence generation and how biopharma companies can sign up.
  • Explore the initial scope and implications of the first planned assessments, with a focus on Oncology and Advanced Therapy Medicinal Products (ATMPs).
  • Identify key areas of alignment and divergence between EU HTA and national processes – and what that could mean for market access strategies.


Please note, this webinar is exclusively available for biopharma companies. Your participation will be anonymous.

Be part of the conversation – register now to explore the early signals, strategic considerations, and what’s coming next for EU HTA. 

Kintiga (formerly MAP Patient Access, AxTalis & SKC) is Europe’s leading independent specialist pharmaceutical and biotechnology management consultancy. Our mission is to partner with health technology developers to elevate client capabilities and expand European market access.  

We provide strategic consulting services to optimise market access, commercialisation, and regulatory success, ensuring innovative treatments reach more European patients faster. 

Our varied webinar programme aims to shine a spotlight on key developments in the market access sphere and share actionable approaches to alleviate some of the pain points that health technology developers face in their everyday work. 

Return to listing